GeneSpark
Advancing global drug treatments for reversible Intellectual Disability disorders through targeted research and innovation.
Advancing global drug treatments for reversible Intellectual Disability disorders through targeted research and innovation.
GeneSpark is an international non-profit foundation established in 2016 with the aim of advancing global drug treatments for reversible Intellectual Disability (ID) disorders caused by gene deletions or mutations. The foundation's primary focus is on addressing Kleefstra syndrome (KS) and related ID disorders through targeted research and innovation. The organization recently received a $30.00K Seed Round investment on 01 March 2016 from Slingshot Accelerator. GeneSpark's dedication to addressing critical healthcare challenges through collaborative drug development makes it an impactful player in the Health Care industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $30.00K | 1 |
|
01 Mar 2016 |
No recent news or press coverage available for GeneSpark.
We care about your data, and we'd love to use cookies make your experience better.
